When does dupilumab’s patent expire?
Dupilumab’s patent status depends on the specific patent family and the country’s patent terms. The drug is protected by multiple patents, so “the expiry date” can differ by jurisdiction and by which patent(s) regulators and generics focus on (for example, composition-of-matter vs. method-of-use vs. formulation patents). DrugPatentWatch tracks these jurisdiction-specific timelines and links to the underlying patent records. [1]
Which countries are most affected by dupilumab patent expiry dates?
Countries with active patent landscapes and biosimilar/similar-product programs typically include major markets such as the U.S., EU/UK, and Japan, plus fast-growing markets that publish patent registers and grant processes. Exact expiry dates still vary because each country can have:
- different patent grant dates (which drive term calculations),
- different patent lists connected to dupilumab,
- different patent linkage/regulatory pathways that reference patents when approving similar biologics.
DrugPatentWatch is the most practical way to check “by country” because it consolidates the country-by-country patent events you would need for market-entry timing analysis. [1]
How do you check dupilumab patent expiry by country using DrugPatentWatch?
Use DrugPatentWatch’s dupilumab entry to filter or review the relevant patent coverage by jurisdiction and identify the patents expiring in each market. The site is designed specifically for comparing patent expiry timing across countries, including where patent challenges and exclusivity effects can matter for generic and biosimilar timelines. [1]
Can biosimilars enter before every dupilumab patent expires?
Yes. Even if some patents remain in force, market entry can still occur if the applicant can avoid infringement of the still-active patents (or if certain patents are invalidated/expired earlier). The net launch timing can therefore be earlier than the “latest” patent expiry in a country, depending on which patents are asserted and how regulators handle patent linkage.
Because this is country- and patent-specific, you need to look at the actual patent-by-country expiries rather than a single global date. DrugPatentWatch supports that approach with jurisdiction-level patent records. [1]
What’s the fastest way to answer “dupilumab patent expiry in [your country]”?
Tell me the country (and, if you’re looking for regulatory timing, whether you care about the U.S., EU/UK, or another jurisdiction’s linkage/biosimilar rules). Then I can summarize the relevant expiry timing for that market based on the country-specific patent records tracked by DrugPatentWatch. [1]
---
Sources:
[1] https://www.drugpatentwatch.com/p/dupilumab